Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP

Hohdatsu, Tsutomu; Ohkawa, Tasuku; Kaneko, Miyuki; Motokawa, Kenji; Kusuhara, Hajime; Kaneshima, Takashi; Arai, Setsuo; Koyama, Hiroyuki

doi:10.1016/j.vetmic.2003.09.016

Cited by 27 publications

(21 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The N protein of the feline infectious peritonitis virus (FIPV) has been used as subunit vaccines to induce protective immunity and to prevent the progression of diseases in a cat model [4]. The literature indicates that immunization of DNA plasmids that encode the N protein of the Ebola virus and influenza virus elicits protective antigen-specific cytotoxic T lymphocyte (CTL) responses [5][6][7].…”

Section: Introductionmentioning

confidence: 99%

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Liu

Leng

Lien

et al. 2006

Vaccine

114

111

View full text Add to dashboard Cite

The recombinant nucleocapsid (rN) protein of the coronavirus (CoV) responsible for severe acute respiratory syndrome (SARS) was cloned and expressed in Escherichia coli, extracted from cell lysates containing 6M urea, then purified by Ni(2+)-affinity chromatography. In animal immunogenicity studies, we found that most anti-rN protein antibodies were IgG2a in BALB/c mice vaccinated with rN emulsified in Montanide ISA-51 containing the synthetic oligodeoxynucleotide, CpG. In contrast, anti-rN protein antibodies of mice immunized with rN protein in PBS were found to mainly be IgG1. These results indicated that ISA-51/CpG-formulated rN protein was dramatically biased toward a Th1 immune response. To identify the B-cell immunodominant epitopes of the rN protein in the mouse and monkey, the reactivities of antisera raised against purified rN proteins formulated in ISA-51/CpG were tested with a panel of overlapping synthetic peptides covering the entire N protein sequence. Three immunodominant linear B-cell epitope regions were mapped to residues 166-180, 356-375, and 396-410 of the rN protein. When the reactivities of these peptides were screened with human sera from five SARS patients, peptides corresponding to residues 156-175 reacted strongly with sera from two of the SARS patients. These results indicated that the region around residues 156-175 of the N protein is immunogenic in the mouse, monkey, and human. We found that peptides corresponding to residues 1-30, 86-100, 306-320, and 351-365 contained murine immunodominant T-cell epitopes. To identify functional CTL epitopes of the N protein, BALB/c mice were immunized with peptides containing the H-2K(d) CTL motif emulsified in adjuvant ISA-51/CpG. Using an IFN-gamma secretion cell assay and analysis by flow cytometry, peptides containing residues 81-95 were found to be capable of stimulating both CD4(+) and CD8(+) cell proliferation in vitro. We also only observed that peptides corresponding to residues 336-350 were capable of stimulating IFN-gamma production in T-cell cultures derived from peripheral blood mononuclear cells (PBMCs) of macaques immunized with the rN protein emulsified in ISA/CpG adjuvant. Our current results together with those of others suggest that some immunodominant B-cell and T-cell epitopes are conserved in the mouse, monkey, and human. This information is very important for the development SARS diagnostic kits and a vaccine.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Liu

Leng

Lien

et al. 2006

Vaccine

114

111

View full text Add to dashboard Cite

show abstract

“…Surprisingly, some Abs that are "neutralizing" in cell culture give rise to "antibody dependent enhancement" (ADE) of infection in vivo. It has been determined that Abs that bind particular viral proteins may exhibit ADE of viral disease while those that bind other viral proteins are protective in vivo (Hohdatsu, et al, 2003 …”

Section: Which Protein In a Multi-protein Structure Binds An Ab Or Grmentioning

confidence: 99%

“…Example [2]: Hohdatsu and colleagues (Hohdatsu, et al, 2003) studied a corona virus (Type II feline infectious peritonitis virus (FIPV)) related to SARS and found that vaccination with the N protein was protective, though not completely, while some antibodies to S caused ADE. The antibodies made in response to vaccination with N protein were not neutralizing and the protection is due to a cellular response.…”

Section: Antibody-dependent Enhancement and Vaccine Designmentioning

confidence: 99%

Mapping the Epitopes of Antibodies

Ladner¹

2007

Biotechnology and Genetic Engineering Reviews

View full text Add to dashboard Cite

“…Different recombinant vaccines based on N protein have already been tested and in some cases they proved to be effective in preventing the progression of FIP. This suggests that a cell mediated immunity against the FIPV antigen was induced by the vaccine (Wasmoen et al, 1995;Hohdatsu et al, 2003) and that therefore N protein could be a suitable vaccine candidate.…”

Section: Introductionmentioning

confidence: 98%

Production of IFN-γ in feline whole blood after incubation with potential T-cell epitopes of the nucleocapsid protein of feline coronavirus

Rossi

Cornaro

Battilani³

et al. 2011

Veterinary Microbiology

View full text Add to dashboard Cite

Interferon gamma (IFN-γ) plays an important role in cell mediated responses against mutated feline coronavirus strains (FCoV) involved in the pathogenesis of feline infectious peritonitis (FIP). The aim of this study was to establish a combined in silico and in vitro approach to assess feline leukocyte production of IFN-γ in response to selected peptides of the nucleocapside protein (N) of FCoVs. To this aim, we designed, through a bioinformatic approach, 8 potentially immunogenic peptides from the protein N corresponding to sequences of residues 14, 182, 198 detected only in FCoVs from FIP cats (virulent strains), only in FCoVs from healthy cats (avirulent strains) and both in FIP and in healthy cats (mixed strains). The peptides or a sham solution were incubated with whole blood from 16 cats (7 healthy and 9 with chronic diseases other than FIP) and IFN-γ concentration was measured on plasma using an ELISA system. RT-PCR expression of IFN-γ mRNA was also evaluated after incubation of the peptides or a sham solution with whole blood from 4 clinically healthy cats. The mean plasma concentration of IFN-γ in samples incubated with peptides decreased and the expression of IFN-γmRNA did not change compared with the sham solution, except for some cats with chronic diseases (which probably have a "pre-activated" immune response). These cats responded to "avirulent" or "mixed" peptides by increasing the concentration of IFN-γ and the expression of IFN-γ mRNA. The combined approach employed in this study allowed us to identify potentially immunogenic peptides of FCoV N protein that can modulate the production of IFN-γ especially in cats with a "pre-activated" cell mediated response.

show abstract

Vaccine efficacy of a cell lysate with recombinant baculovirus-expressed feline infectious peritonitis (FIP) virus nucleocapsid protein against progression of FIP

Cited by 27 publications

References 25 publications

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates

Mapping the Epitopes of Antibodies

Production of IFN-γ in feline whole blood after incubation with potential T-cell epitopes of the nucleocapsid protein of feline coronavirus

Contact Info

Product

Resources

About